Yttrium-90 Radioembolization of Hepatic Metastases from Colorectal Cancer by Raval, Mihir et al.
 
Yttrium-90 Radioembolization of Hepatic Metastases from
Colorectal Cancer
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Raval, Mihir, Dinesh Bande, Anil K. Pillai, Lawrence S.
Blaszkowsky, Suvranu Ganguli, Muhammad S. Beg, and
Sanjeeva P. Kalva. 2014. “Yttrium-90 Radioembolization of
Hepatic Metastases from Colorectal Cancer.” Frontiers in
Oncology 4 (1): 120. doi:10.3389/fonc.2014.00120.
http://dx.doi.org/10.3389/fonc.2014.00120.
Published Version doi:10.3389/fonc.2014.00120
Accessed February 16, 2015 9:16:55 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785941
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 25 July 2014
doi: 10.3389/fonc.2014.00120
Yttrium-90 radioembolization of hepatic metastases from
colorectal cancer
Mihir Raval
1, Dinesh Bande
2,3,4,Anil K. Pillai
5,6, Lawrence S. Blaszkowsky
7,8,9, Suvranu Ganguli
7,10,11,
Muhammad S. Beg
5,12 and Sanjeeva P . Kalva
5,6*
1 Department of Hospital Medicine, Essentia Health, Fargo, ND, USA
2 Department of Hospital Medicine, Sanford Health, Fargo, ND, USA
3 Roger Maris Cancer Center, Fargo, ND, USA
4 Department of Internal Medicine, University of North Dakota, Fargo, ND, USA
5 Harold Simmons Cancer Center, University ofTexas Southwestern Medical Center, Dallas,TX, USA
6 Interventional Radiology, University ofTexas Southwestern Medical Center, Dallas,TX, USA
7 Massachusetts General Hospital Cancer Center, Boston, MA, USA
8 Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
9 Department of Medicine, Harvard Medical School, Boston, MA, USA
10 Section of Interventional Radiology, Department of Imaging, Massachusetts General Hospital, Boston, MA, USA
11 Department of Radiology, Harvard Medical School, Boston, MA, USA
12 Division of Hematology and Oncology, Department of Medicine, University ofTexas Southwestern Medical Center, Dallas,TX, USA
Edited by:
Kathy Willowson, University of
Sydney, Australia
Reviewed by:
Athanasios Zafeirakis, 401 Army
Hospital of Athens, Greece
Mustafa Erkan Altinyay, National
Guard Health Affairs, Saudi Arabia
*Correspondence:
Sanjeeva P . Kalva, Interventional
Radiology, University ofTexas
Southwestern Medical Center, 5323
Harry Hines Blvd, Dallas,TX
75390-8834, USA
e-mail: sanjeeva.kalva@
utsouthwestern.edu
Liver metastases from colorectal cancer (CRC) result in substantial morbidity and mortality.
The primary treatment is systemic chemotherapy, and in selected patients, surgical resec-
tion; however, for patients who are not surgical candidates and/or fail systemic chemother-
apy, liver-directed therapies are increasingly being utilized. Yttrium-90 (Y-90) microsphere
therapy, also known as selective internal radiation therapy (SIRT) or radioembolization, has
proven to be effective in terms of extending time to progression of disease and also pro-
viding survival beneﬁt.This review focuses on the use ofY-90 microsphere therapy in the
treatment of liver metastases from CRC, including a comprehensive review of published
clinical trials and prospective studies conducted thus far. We review the methodology,
outcomes, and side effects ofY-90 microsphere therapy for metastatic CRC.
Keywords: colorectal cancer, liver metastases, radioembolization,Yttrium-90 microspheres,Y-90 therapy, selective
internal radiation therapy
INTRODUCTION
The liver is the most common site of metastases from colorec-
tal cancer (CRC). Approximately 20% of patients are found
to have distant metastases at the time of CRC diagnosis with
approximately 40% to the liver (1, 2). An additional 35–60%
of patients develop liver metastases in the course of the disease.
Presence of liver metastases portends a poor prognosis. Of the
patients who develop liver metastases, one-ﬁfth dies with liver
metastases only. In the absence of treatment, the median sur-
vival is approximately 4–6months. Surgical resection of liver
metastases provides the best 5-year survival, in the order of
40%, and is possible if the disease is localized or downgraded
with systemic chemotherapy and a safe surgical margin can be
achieved without signiﬁcant post-operative liver dysfunction (3–
5). Only 10–20% of patients who present with liver metastases
from CRC are surgical candidates (2–5). The role of standard
external beam radiation has been limited due to poor toler-
ance of the normal liver tissue to radiation. As such, pallia-
tive chemotherapy had for many years been the only option
for the majority of patients with liver metastases from CRC.
The ﬂuropyrimidine 5-ﬂuorouracil has been used in the man-
agement for several decades. The introduction of several new
cytotoxic agents, including oxaliplatin, irinotecan, and targeted
therapies including VEGF and EGFR inhibitors, has resulted in
substantial improvement in median survival, which now exceeds
2years (6–9).
Since the majority of CRC metastases occur in the liver and
the beneﬁt from systemic chemotherapy has been modest until
recently, selective hepatic arterial chemotherapy through arte-
rial infusion of 5-ﬂuorouracil has been practiced with mixed
results (10, 11). Such therapy is based on the principle that the
metastases receive the majority of blood ﬂow from the hepatic
artery (12) and direct arterial infusion of chemotherapeutic drugs
would result in higher tumoral concentration of the drugs com-
pared to those achieved with intravenous administration due to
high ﬁrst pass hepatic extraction of the drugs (13). New regi-
mens of systemic chemotherapy have virtually replaced hepatic
artery infusion chemotherapy due to better results (6). How-
ever, there has been resurgence of hepatic artery directed thera-
pies through the use of microparticles that either carries radia-
tion (radioembolization) or chemotherapeutic drugs (chemoem-
bolization)(14).Inthisarticle,wepresenttherationale,treatment
aspects, and results of radioembolization in the treatment of
hepatic colorectal metastases.
www.frontiersin.org July 2014 | Volume 4 | Article 120 | 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Raval et al. Yttrium-90 radioembolization
RATIONALE OF RADIOEMBOLIZATION THERAPY
Radioembolization withYttrium-90 (Y-90) microspheres is based
onthesameprincipleasthatofhepaticarteryinfusionchemother-
apy. The hepatic artery provides the primary vascular supply
to the tumor with >80% of the blood ﬂow to the tumor
being derived from the hepatic artery whereas the normal liver
parenchyma receives the majority of its blood ﬂow via the por-
tal vein (12). In addition, the microvascular density of the
hepatic tumors is 3–200 times higher than the surrounding
normal liver parenchyma (15) leading to a higher localized
entrapment of microparticles in the tumor when the micropar-
ticles are infused through the hepatic artery. CRC cells are
highly radiosensitive and do not demonstrate any cross-resistance
to radiation despite being chemotherapy-refractory. Addition-
ally, radiation works synergistically when used with radiation-
sensitizing chemotherapeutic drugs. Unlike external beam radi-
ation, which is limited to treatment of small number of focal
tumors due to concerns of liver toxicity with multi-focal dis-
ease, selective infusion of Y-90 microspheres allows selective
“inside-out” radiation of multi-focal tumors through selective
localization of the particles in the tumor vessels and local-
ized emission of beta radiation in the tumor environment
(14). Because of this, Y-90 radioembolization is also known
as “selective internal radiation therapy” (SIRT) or intra-arterial
brachytherapy.
YTTRIUM-90 MICROSPHERES
The ﬁrst intra-arterial infusion of Y-90 radio-isotope for treat-
ment of pancreatic and primary liver cancer was reported in
1965 (16). Since that time,there have been signiﬁcant advances in
the production,distribution,and administration of these micros-
pheres. Currently, there are two commercially available Y-90
labeled microsphere preparations – TheraSpheres (BTG Interna-
tional Canada Inc, Ottawa, ON, Canada) and SIR-spheres (Sirtex
Medical Inc., Sydney, NSW, Australia). Both microspheres mea-
sure 20–60mm in size (TheraSpheres 20–30mm and SIR-spheres,
20–60mm), and are designed to carry Y-90. Y-90 is a beta radi-
ation emitter, with a half-life of 64.1h and an average energy of
0.94MeV. The radiation has a range of 1.1cm (average 2.5mm
in the tissues) from the source, and 94% of the dose is deliv-
ered within the ﬁrst 11days following administration (14). The
microspheres remain embedded in the vascular bed permanently
without undergoing any physical or chemical change. The major
differences between the two preparations are the density and spe-
ciﬁc activity (radiation dose per microsphere) of the particles,
and their FDA approval (17, 18). TheraSpheres are made of glass
and Y-90 is embedded within the glass matrix leading to higher
density and speciﬁc activity (2500Bq) of the preparation. SIR-
spheres are made of resin and Y-90 is coated on the surface of the
particle leading to low density and low speciﬁc activity (50Bq).
The FDA approved TheraSpheres under the category of human-
itarian device exemption for use in patients with unresectable
hepatocellular carcinoma requiring on site institutional review
board(IRB)oversight.SIR-spheresreceivedFDAapprovalin2002
as a brachytherapy device for treatment of unresectable hepatic
metastases from CRC with adjuvant hepatic artery infusion of
ﬂoxuridine.
ADMINISTRATION OF YTTRIUM-90 MICROSPHERES
A successful intra-tumoral administration of Y-90 microspheres
involvescarefulpatientselection,assessmentofthehepaticarteries
and hepato-pulmonary shunt, dose calculation,and intra-arterial
delivery of the microspheres.
PATIENT SELECTION
Carefulevaluationforoptimalpatientselectionisrequiredtoopti-
mize the outcomes and limit toxicities of Y-90 radioembolization.
The recommended selection criteria are listed in Table 1 (19).
Patients with poor performance status, limited hepatic reserve,
and extensive multi-organ metastases are poor candidates for this
therapy. At many centers, baseline evaluation is performed with
PET-CT to detect extra-hepatic disease and to assess the volume
and biological activity of the tumor.
ASSESSMENT OF HEPATIC ARTERIES AND HEPATO-PULMONARY
SHUNT
Selective intra-arterial infusion of Y-90 microspheres requires
careful angiographic evaluation of the hepatic arteries to plan for
lobar or segmental delivery of the microspheres,to isolate hepatic
perfusion to a few arteries (so as to minimize the number of
infusions or to minimize risks of extra-hepatic delivery) and to
pro-actively exclude the hepatic artery branches (such as the gas-
tric or duodenal arteries) that are at risk of non-targeted delivery
of the microspheres. The hepatic arterial branches that are at risk
of non-target delivery are occluded (embolized) with coils.
The hepato-pulmonary shunt can lead to non-target deposi-
tion of Y-90 microspheres in the lung. Some of the microspheres
escapetheliverthroughlarge(>30mmindiameter)intra-tumoral
arteriovenous shunts and get entrapped in the pulmonary capil-
laries. The degree of shunting is estimated through intra-arterial
infusion of Tc-99m macro-aggregated albumin (4–5mCi) and
subsequentmeasurementofthelungandliveractivityonagamma
camera. Presence of hepato-pulmonary shunt per se is not a
contra-indication for treatment with Y-90 microspheres as long
as the radiation dose per treatment to the lung does not exceed
30Gy or the cumulative dose to the lungs is within 50Gy.
DOSE CALCULATION
Dose calculation is based on the tumor volume in the liver (20).
Two methods popularly used include the empiric method and the
body surface area (BSA) method. In the empiric method, 2GBq
of Y-90 dose is given for a tumor volume occupying <25% of
the liver, 3GBq if the tumor volume is 25–50% of the liver vol-
ume, and 5GBq if the tumor volume exceeds >50% of the liver
volume. BSA method takes in to consideration of the BSA, liver
volume, and tumor volume and is tailored to the patient and
the volume of the liver treated. The calculated dose in gigabec-
querel is [(BSA 0.2)C{Tumor volume/(Tumor volumeCLiver
volume)}]. Many centers in the US follow BSA method for dose
calculation(19,21,22).Treatmentbasedonthedosecalculatedby
the empiric method (especially when the tumor volume exceeds
>25%) results in very high, often fatal, radiation dose to the liver
and is not recommended. The dose calculations for TheraSpheres
are based on partition model with an intent to deliver 80–120Gy
of radiation dose to the treated volume of the liver.
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Table 1 | Patient selection criteria forYttrium-90 radioembolization of hepatic metastases from colorectal cancer.
TUMOR SPECIFIC
Liver metastases not eligible for surgery or local ablative therapy
Failed ﬁrst line systemic chemotherapy (unless planning for concomitant systemic chemotherapy)
No signiﬁcant hepato-pulmonary shunt (which results from presence of large intra-tumoral arteriovenous shunts). Radioembolization is not performed if
the radiation dose to the lung exceeds 30Gy per treatment
Absent or minimal extra-hepatic metastases
LIVER SPECIFIC
Relatively preserved liver and kidney function – serum bilirubin <2mg/dL, serum creatinine <1.8mg/dL; platelet count >50,000/mL
Preserved hepatopetal ﬂow in the main portal vein
No risk of non-target delivery of the microspheres during hepatic arterial infusion
No prior radiation to the liver
PATIENT SPECIFIC
ECOG performance status of 2 or less
Life expectancy of >6weeks
FIGURE 1 |Assessment of response toY-90 therapy on PET. A PET scan (A) obtained prior toY-90 therapy demonstrates three FDG avid lesions. A repeat
PET scan (B) obtained 6weeks afterY-90 therapy shows no FDG avid lesions suggesting complete metabolic response.
INFUSION OF YTTRIUM-90 MICROSPHERES
SelectiveinfusionofY-90microspheresisachievedthroughclosed
circuitdeliveryusingproprietarydeliverydevicethatisspeciﬁcfor
each company. Both lobar and whole liver infusions are practiced;
authorsprefertouselobarorsegmentalinfusionsoverwholeliver
infusionsinordertolimithepatictoxicities.Postinfusionimaging
of theliverthroughSPECTorPETisoftenperformed(thoughnot
required)toassessthehepaticuptakepatternof themicrospheres.
PATIENT FOLLOW-UP AND SUBSEQUENT TREATMENTS
When not contraindicated, some centers administer systemic 5-
ﬂuorouracil before and after Y-90 therapy. Toxicities are assessed
at 1 and 4weeks followingY-90 therapy. In the presence of bilobar
disease,Y-90 radioembolization of the other lobe is performed at
4–6weeks from initial therapy. A follow-up PET-CT is performed
at 6weeks after second treatment. There are no standardized
guidelines on timing of follow-up imaging studies to assess tumor
response. PET has been shown to be useful in assessing response
and guiding further treatment (Figure 1); the role of CT atten-
uation change of the tumor as a surrogate marker of response is
currently being explored (Figure 2) (23–25). Subsequent imag-
ing assessment is performed at 3month intervals with PET-CT.
Additional Y-90 infusions are performed (up to two treatments
per lobe) if tumor recurs.
TOXICITIES
Mostpatientsreportfever,lethargy,decreasedappetite,andfatigue
following therapy. Uncommon serious adverse events include
radiation-induced gastric ulcers, lymphocytopenia, jaundice,
cholecystitis,lungtoxicity,hepaticabscess,radiationhepatitis,and
liver failure (26–29). Patients are advised to take proton pump
inhibitors to prevent gastrointestinal side effects. Use of peri-
procedural steroids to prevent development of fatigue or chronic
liver injury is also described (29). The hepatic injury from Y-90
appears to be secondary to development of portal triaditis (29).
OUTCOMES
Given that Y-90 radioembolization for hepatic colorectal metas-
tases has been used at various stages of the disease and with or
without systemic or regional chemotherapy, the outcomes of this
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FIGURE 2 |Assessment of response toY-90 therapy on CT. A contrast
enhanced CT scan (A) of the liver demonstrates hypo-attenuating lesions
(arrows) in the liver. A repeat contrast enhanced CT scan (B) obtained 6weeks
afterY-90 therapy shows very low attenuation of the lesions (arrows). Even
though the lesions size has not signiﬁcantly changed, the development of very
low attenuation on post-treatment scan suggests response toY-90 therapy.
Table 2 |Yttrium-90 radioembolization as ﬁrst line therapy for hepatic colorectal metastases.
Author No. of patients Trial design Treatment Response Survival Complications
Gray et al.
(30)
74 (only 70
included in
analysis)
Prospective, phase
III, randomized
Y-90 radioembolization
plus hepatic arterial
chemoinfusion (HAC)
with ﬂoxuridine (nD36)
vs. HAC with ﬂoxuridine
(nD34)
Response
(CRCPR): 44
vs. 17 .6%
(p D0.001)
response
(CEA): 72 vs.
47%
(p D0.004)
TTP: 15.9 vs. 9.7m
(p D0.001); 1, 2, 3, and
5year survivals: 72, 39,
17 , 3.5 vs. 68, 29, 6.5,
and 0%; median
survival: 17 vs. 15.9m
(p D0.18)
Higher incidence of grade 3
elevation of alkaline
phosphatase in the group that
receivedY-90 plus HAC; no
overall difference in the
incidence of grade 3–4
toxicities among the two
groups
Van Hazel
et al. (31)
21 Prospective, phase
II, randomized
Y-90 radioembolization
plus systemic
5-ﬂuorouracil and
leucovorin (nD11) vs.
systemic 5-ﬂuorouracil
and leucovorin (nD10)
Best
conﬁrmed
response:
8PR, 3SD vs.
0PR, 6SD, 4PD
(p <0.001)
Median survival: 29.4
vs. 12.8m (p D0.02).
PFS: 18.6 vs. 3.4m
Grade 3 and 4 toxicity events:
13 vs. 5; No difference in
quality of life
Sharma
et al. (32)
20 Prospective, single
arm; patients with
unresectable
disease and
chemo-naive
Y-90 radioembolization
plus FOLFOX
18PR, 2SD TTP: 12.3m in patients
with EHD, 14.2m in
patients without EHD.
Median PFS:
9.3months
Grade 3–4 neutropenia in 12.
Gastric ulcer in 1. Grade 3
hepatotoxicity in 1
Kosmider
et al. (33)
19 Retrospective Y-90 radioembolization
plus 5-ﬂuorouracil and
leucovorin (nD7) or
FOLFOX (nD12)
ORR: 84%
(2CR, 14PR)
PFS: 10.4m; OS:
29.4m; signiﬁcantly
better survival if no
EHD (37 .8 vs. 13.4m)
Febrile neutropenia with
concurrent FOLFOX
treatment, a perforated
duodenal ulcer, and one death
from hepatic toxicity
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression free survival; EHD, extra-hepatic disease; ORR, objective
response rate; OS, overall survival; CEA, carcinoembryonic antigen;TTP , time to progression; HAC, hepatic arterial chemoinfusion.
therapy are described in this manuscript according to the timing
of this therapy and systemic chemotherapy.
YTTRIUM-90 RADIOEMBOLIZATION AS FIRST LINE THERAPY
The ﬁrst prospective study that led to FDA registration of Y-90
microspheres (SIR-spheres) for treatment of hepatic metastases
from CRC included 74 patients who were randomized to receive
hepatic arterial chemoinfusion (HAC) of ﬂoxuridine and single
wholeliverY-90therapythroughhepaticarteryaccessportorHAC
of ﬂoxuridine alone (Table 2) (30). The ﬁnal analysis included 70
patients. There was signiﬁcantly higher objective response rate
in patients who received Y-90 microsphere therapy in addition
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Table 3 |Yttrium-90 radioembolization in combination with second- or third-line chemotherapy.
Author No. of patients Trial design Treatment Response Survival Complications
Van Hazel
et al. (34)
25 Prospective, dose
escalation study
Irinotecan at 50, 75,
or 100mg/m2 on
days 1 and 8 of a
3-week cycle for the
ﬁrst two cycles, and
full irinotecan doses
(i.e., 100mg/m2)
during cycles 3–9.
Radioembolization
during the ﬁrst
chemotherapy cycle
PR in 11 (48%) of
23, and SD in 9
(39%)
Median PFS:
6.0months;
Median OS:
12.2months
Grades 3–4 events in three of six
patients at 50mg/m2 (obstructive
jaundice, thrombocytopenia, and
diarrhea), in ﬁve of 13 patients at
75mg/m2 (neutropenia, leukopenia,
thrombocytopenia, elevated alkaline
phosphatase, abdominal pain, ascites,
and fatigue) and in four of six patients
at 100mg/m2 (diarrhea, deep vein
thrombosis, constipation, and
leukopenia)
Lim et al.
(35)
30 Prospective; all
patients who
failed initial 5-FU
chemotherapy, 22
failed oxaliplatin
or irinotecan also.
EHD in 7
Radioembolization;
concurrent 5FU in 21
PR in 10 (33%); SD
in 8 (27%); no
response in
patients with poor
performance status
or with extra
hepatic disease
TTP:
5.3months
Duodenal/gastric ulcer in 13%. One
death related to radiation hepatitis
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression free survival; EHD, extra-hepatic disease; ORR, objective
response rate; OS, overall survival; CEA, carcinoembryonic antigen;TTP , time to progression; HAC, hepatic arterial chemoinfusion.
to HAC compared to those who received HAC alone (Response
rate based on WHO criteria at 3months was 44.4 vs. 17.6%,
p D0.01) (30). More patients in the Y-90 group demonstrated
50% or more reduction in elevated CEA levels following ther-
apy (72.2 vs. 47.1%, p D0.004) (30). The median time to tumor
progression (TTP) was longer in the group that received Y-90
(15.9 vs. 9.7months). Though a trend for a survival advantage in
this group was observed, it did not reach statistical signiﬁcance.
Authors also reported 3.1 times (95% CI: 1.1–8.8) higher risk of
deathfromprogressionoflivermetastasesinpatientswhoreceived
HAC alone. There were no signiﬁcant differences in the incidence
of Grade 3 or 4 toxic events in either group. This study is signiﬁ-
cantinthatitdemonstratedsafetyofY-90therapywhencombined
with HAC of ﬂoxuridine and such addition deﬁnitively improved
objective response rate and TTP in predominately chemo-naive
patients. However, the study failed to demonstrate any signiﬁcant
survival advantage of such combination therapy. This may be due
to the small number of patients enrolled in this study. Secondly,
the study randomized patients to HAC with ﬂoxuridine, which
is rarely used as ﬁrst line therapy. The ﬁrst line chemotherapy
currentlyemployedincludesacombinationof 5-ﬂuorouracil,leu-
covorinplusoxaliplatin,oririnotecan(FOLFOXorFOLFIRI)with
or without biological agents such as bevacizumab.
A subsequent phase 2 study by the same group addressed
some of the issues related to the ﬁrst study (31). Patients were
randomizedtoreceivesystemicchemotherapywith5-ﬂuorouracil
andleucovorinaloneorincombinationwithasinglehepaticartery
infusion of Y-90 resin microspheres (Table 2). The results sup-
portedthefactthattheadditionof singleinfusionofY-90micros-
pheres resulted in signiﬁcantly higher objective response rate
(ORR: 90.1 vs. 0%; p <0.001), longer TTP (18.6 vs. 3.6months;
p <0.0005), and better median survival (29.4 vs. 12.8months;
p D0.025). This study was limited by the small patient cohort
(totalof 21patientsonly)anduseof 5-FUandleucovorinonlyfor
chemotherapy.
Sharma et al.,in a phase 1 study,assessed the toxicity and max-
imum tolerated dose of oxaliplatin during the ﬁrst three cycles of
chemotherapy (FOLFOX) when used as a radiation sensitizer for
Y-90 therapy that was administered within 3–4days of ﬁrst cycle
of chemotherapy (Table 2) (32). Patients received standard dose
oxaliplatin from the fourth cycle of chemotherapy (FOLFOX).
Most of the patients with bilobar disease received sequential lobar
infusion of Y-90 microspheres. The maximum tolerated dose was
60mg/m2 of oxaliplatin for the ﬁrst three cycles, with full dose
FOLFOXthereafter.Thetoxicitywaslimitedtograde3abdominal
paininﬁvepatients,Grade3–4neutropeniain12andoneepisode
of Grade 3 hepatotoxicity. They reported a 90% partial response
(PR) rate at 12weeks, median progression free survival (PFS) of
9.3months and TTP of 12.3months. In patients with no extra-
hepatic disease,the PFS was 14.2months. This study is signiﬁcant
in that it demonstrated the safety of combiningY-90 therapy with
standard ﬁrst line systemic chemotherapy (FOLFOX). Since it is a
phase I study without randomization to a chemotherapy alone
arm, it is difﬁcult to draw conclusions on the effectiveness of
such combination therapy. The median PFS and overall survival
reportedbytheauthorswhoappliedFOLFOXregimenusedasﬁrst
linechemotherapywithoutY-90radioembolizationrangefrom7.6
to 9.0months and 16.2 to 19.5months, respectively.
In a retrospective review, Kosmider et al. reported results
of combination therapy with Y-90 microspheres and systemic
chemotherapy with FOLFOX or 5-FUCleucovorin as ﬁrst line
therapy for hepatic metastases from colon cancer (Table 2) (33).
The reported objective response rate was 84% with a median PFS
of 10.4months and median survival of 29.4months. The median
www.frontiersin.org July 2014 | Volume 4 | Article 120 | 5 
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Table 4 |Yttrium-90 as salvage therapy for chemorefractory patients.
Author No. of
patients
Trial design Treatment Response Survival Complications
Kennedy
et al. (19)
506 Retrospective, multi-center;
extra-hepatic disease in 35%;
90% received prior
chemotherapy and 30%
received liver surgery or
ablation
Radioembolization
withY-90
Median OS:
10.1months
Total Grade 1–3 events: 32%
gastrointestinal events, 44%
fatigue, and 1% liver failure
Kennedy
et al. (21)
208 Retrospective, multi-center;
100% failed ﬁrst line
chemotherapy
(FOLFOXAvastin/Erbitux),
94% failed second line
(FOLFIRIAvastin/Erbitux),
and 87% failed third line
chemotherapy
(CapecitabineAvastin/Erbitux);
46% had liver-directed
therapies
Radioembolization
withY-90
Median OS
10.5months for
responders and
4.5months for
non-responders
Computed tomography
partial response was 35%;
positron emission
tomography response of
91%
Cianni et al.
(36)
41 Retrospective; all patients
progressed on several
systemic chemotherapy
regimens
Radioembolization
withY-90
CR in 2, PR in
17 , SD in 14,
and PD in 8
patients
Median OS:
354days, median
PFS: 279days
One Grade 4 hepatic failure,
two Grade 2 gastritis, and
one Grade 2 cholecystitis
Hendlisz
et al. (37)
46 (44
Analyzed)
Prospective, multi-center, and
randomized study
Patients who failed
systemic
chemotherapy
were randomized
to receive 5FU (26)
or 5FU plusY-90
(24)
MedianTTLP was
2.1 vs. 5.5m;
medianTTP was 2.1
vs. 4.5m; median
OS: 7 .3. 10m
No signiﬁcant toxicities in
the group, which received
5FU andY-90
Cosimelli
et al. (38)
50 Multi-center, phase II
prospective study; 38 patients
had 4 lines of chemotherapy
Radioembolization
withY-90
CR in 1, PR in
11, SD in 12,
and PD in 22.
Medina OS 12.6m;
improved survival in
patients who
responded toY-90
(16 vs. 8m)
Two deaths in 2months
Bester et al.
(39)
224 vs. 51 Retrospective case control
study;Y-90 vs. best supportive
care for chemorefractory liver
metastases
Radioembolization
withY-90 vs. best
supportive care
Median OS 11.6 vs.
6.3m
11 Cases (3%) of ulceration,
10 cases (2.9%) of
radiation-induced liver
disease, and 6
complications (1.8%)
involving the gallbladder
(e.g., cholecystitis)
Evans et al.
(40)
140 Retrospective study; 35%
extra hepatic disease
Radioembolization
withY-90
Median OS
7 .9months
Saxena
et al. (22)
979 Systematic review of 20
studies; patients aﬁeld
median 3 regimens of
chemotherapy
CR: 0%, PR:
31%; SD:
40.5%
MedianTTLP
9months. Median
OS 12months
Mostly Grade 1 and 2
toxicities
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression free survival; EHD, extra-hepatic disease; ORR, objective
response rate; OS, overall survival; CEA, carcinoembryonic antigen;TTP , time to progression;TTLP , time to progression in the liver; HAC, hepatic arterial chemoinfusion.
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survival was signiﬁcantly better in patients with no extra-hepatic
disease (37.8 vs. 13.4m). This study is limited by small number
(only 19 patients),retrospective nature,and varied chemotherapy
regimens used.
In summary, Y-90 therapy in combination with ﬁrst line
chemotherapy is safe and may improve tumor response rates.
Although a trend toward improved overall survival is reported,
moredataisrequiredtoestablishitsroleinimprovingoverallsur-
vivaloutcomes.Thereareafewlargeongoingclinicalstudies(SIR-
FLOX trial:NCT00724503 and FOXFIRE trial:ISRCTN83867919)
that include current standard of care chemotherapy regimens
(with biological agents) with Y-90 and may help establish the
beneﬁt of Y-90 as part of ﬁrst line therapy.
YTTRIUM-90 RADIOEMBOLIZATION IN COMBINATION WITH SECOND-
OR THIRD-LINE CHEMOTHERAPY
Van Hazel et al. reported results of concomitant therapy of Y-90
radioembolization with systemic irinotecan in patients who failed
initial5-FUchemotherapy(Table3)(34).Irinotecanwasadminis-
tered to assess maximum tolerated dose. In a group of 25 patients,
11 (48%) patients had PR and 9 (39%) had stable disease (SD).
Themedianoverallsurvivalwas12.2months.Grade3–4toxicities
occurred in 12 (48%) patients.
In another study, Lim et al. reported results from a hetero-
geneous group of patients (n D30) who were treated with 5-FU
as ﬁrst line chemotherapy (Table 3) (35). Eight of these patients
failed 5-FU, 14 patients failed 5-FU and subsequent oxaliplatin
and irinotecan, and 8 patients failed 5-FU and subsequent oxali-
platin or irinotecan. Thirty-three percent had PR and TTP was
5.3months. There was 13% incidence of duodenal/gastric ulcers
from non-target embolization of Yttrium-90 microspheres.
YTTRIUM-90 RADIOEMBOLIZATION AS A SALVAGE TREATMENT FOR
CHEMOTHERAPY-REFRACTORY DISEASE
Multiple retrospective studies reported outcomes when Y-90 was
used as salvage therapy in chemorefractory patients (Table 4)
(19, 21, 22, 36–40). Bester et al. reported the results of a ret-
rospective study to evaluate the safety and survival of patient
with chemotherapy-refractory metastatic CRC to the liver treated
with resin microsphere Y-90 (n D224) compared with patients
who underwent standard/supportive care (n D51) (Table 4)
(39). The median overall survival after radioembolization was
11.9monthscomparedto6.3monthsforthestandardcarecohort.
The incidence of duodenal/gastric ulceration was 3.2%.
In a phase II multi-centered clinical trial for chemotherapy-
refractorycolorectallivermetastasis,Cosimellireportedanoverall
response rate of 24% using the RECIST criteria (38). The median
time to progression was 3.7months and the median overall sur-
vival was 12.6months. Apart from two deaths at 40days (from
renal failure) and 60days (liver failure) after treatment, all of
their adverse events were classiﬁed within the WHO Grade 1/2
category. Two patients from their cohort were downsized with
radioembolization to enable potential curative resection.
A recent systematic review by Saxena et al. (n D979) reported
a median time to intrahepatic progression of 9months and a
median overall survival of 12months, the overall acute toxicities
ranged from 11 to 100% (median 41%) with most of the cases
being mild – Grade 1/2 (median 39%), which resolved without
intervention (22).
Overall, median survival is in the range of 10–12months in
these studies. The response rates are at 31% PR and 41% SD
(22). Presence of large volume disease (>25% of liver volume),
extra-hepatic disease, poor response to Y-90, and 3 lines of
prior chemotherapy portend poor prognosis (22). Given that the
median survival of patients who failed third line chemotherapy is
in the range of 4–6months, therapy with Y-90 may improve sur-
vival outcomes. The utility of concomitant chemotherapy needs
to be further explored.
RECOMMENDATIONS
Yttrium-90therapyisrecommendedforchemorefractorypatients
with liver-only or liver-predominant disease and in patients who
donotwishtohavesystemicchemotherapy.UseofY-90therapyin
conjunction with standard ﬁrst line or second line chemotherapy
requires more rigorous data and is recommended in a clinical
trial setting. The use of Y-90 is not recommended in patients
with extensive extra-hepatic disease or extensive bilobar hepatic
involvement. Similarly, patients with poor performance status
(ECOG PS >2) are not suitable forY-90 therapy.
CONCLUSION
Yttrium-90 microsphere therapy is being increasingly used for
treatment of colorectal metastases to the liver. Patients who have
failed systemic chemotherapy appear to beneﬁt from this therapy.
Concurrent use of Y-90 in ﬁrst and second line chemotherapy is
currently being investigated. Future trials need to focus on identi-
fying speciﬁc target populations who may beneﬁt most from this
therapy.
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